Agung Pranata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agung Pranata has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dedy Syahrizal
Universitas Syiah Kuala
1 shared publication - Fauzul Husna
Department of Pharmacology, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
1 shared publication - Jufriady Ismy
Division of Urology, Department of Surgery, Dr. Zainoel Abidin General Hospital, Universitas Syiah Kuala, Banda Aceh, Aceh, 23230
1 shared publication - Maryatun Hasan
Department of Internal Medicine, Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia
1 shared publication - Rika Farhana
Universitas Syiah Kuala
1 shared publication - Wahyu Eka Sari
Center for Tropical Veterinary Studies-One Health Collaboration Center, Universitas Syiah Kuala, Banda Aceh, Indonesia; Veterinary Public Health Laboratory, Faculty of Veterinary Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 23 (2)
Mesenchymal stem cell-derived secretome may attenuate nephrotoxicity by modulating cyclooxygenase-2 and caspase-3 levels in Wistar rats: an ELISA-based analysis
Aim: Nephrotoxicity is a major clinical concern because it can impair kidney function through inflammation and apoptosis. This study aimed to evaluate the effects of mesenchymal stem cell (MSC)-derived secretome on cyclooxygenase-2 (COX-2) and caspase-3 levels in a rat model of doxorubicin-induced nephrotoxicity. Methods: A total of 24 male Wistar rats were randomly allocated into four groups: normal control (NC), nephrotoxicity control (TC), early MSC-derived secretome treatment (P1), and delayed MSC-derived secretome treatment (P2). Nephrotoxicity was induced using a single intraperitoneal injection of doxorubicin (10 mg/kg body weight). MSC-derived secretome was administered intravenously (0.15 mL) immediately after doxorubicin injection in the P1 group, and administered to the P2 group on day 5 after doxorubicin injection. All rats were euthanised on day 12. COX-2 and caspase-3 levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: A significant overall difference in COX-2 levels was observed among groups (p = 0.035). A strong, statistically significant positive correlation was observed between COX-2 and caspase-3 levels (r = 0.684, p = 0.002). The lowest COX-2 levels were found in the P1 group. No significant differences in caspase-3 levels were observed. Conclusion: This study showed a significant overall difference in renal COX-2 levels among groups in a doxorubicin-induced nephrotoxicity rat model; however, Holm-adjusted post hoc comparisons did not confirm significant pairwise differences. Caspase-3 levels did not differ significantly among groups. These findings suggest that MSC-derived secretome may have potential anti-inflammatory effects, particularly when administered early after doxorubicin exposure, but further studies are required to confirm its effects on renal inflammation and apoptosis.
- 17 June 2026
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 23 (2)
Open AccessMesenchymal stem cell-derived secretome may attenuate nephrotoxicity by modulating cyclooxygenase-2 and caspase-3 levels in Wistar rats: an ELISA-based analysis
Aim: Nephrotoxicity is a major clinical concern because it can impair kidney function through inflammation and apoptosis. This study aimed to evaluate the effects of mesenchymal stem cell (MSC)-derived secretome on cyclooxygenase-2 (COX-2) and caspase-3 levels in a rat model of doxorubicin-induced nephrotoxicity. Methods: A total of 24 male Wistar rats were randomly allocated into four groups: normal control (NC), nephrotoxicity control (TC), early MSC-derived secretome treatment (P1), and delayed MSC-derived secretome treatment (P2). Nephrotoxicity was induced using a single intraperitoneal injection of doxorubicin (10 mg/kg body weight). MSC-derived secretome was administered intravenously (0.15 mL) immediately after doxorubicin injection in the P1 group, and administered to the P2 group on day 5 after doxorubicin injection. All rats were euthanised on day 12. COX-2 and caspase-3 levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: A significant overall difference in COX-2 levels was observed among groups (p = 0.035). A strong, statistically significant positive correlation was observed between COX-2 and caspase-3 levels (r = 0.684, p = 0.002). The lowest COX-2 levels were found in the P1 group. No significant differences in caspase-3 levels were observed. Conclusion: This study showed a significant overall difference in renal COX-2 levels among groups in a doxorubicin-induced nephrotoxicity rat model; however, Holm-adjusted post hoc comparisons did not confirm significant pairwise differences. Caspase-3 levels did not differ significantly among groups. These findings suggest that MSC-derived secretome may have potential anti-inflammatory effects, particularly when administered early after doxorubicin exposure, but further studies are required to confirm its effects on renal inflammation and apoptosis.
- Open Access
- 16 May 2023
- Published by DiscoverSys, Inc. in Bali Medical Journal
- Vol. 12 (3) , 3326-3330
The prevalence of long COVID symptoms in Indonesia: a cross-sectional study in Aceh
Introduction: It is estimated that the long-term consequences of Coronavirus Disease 2019 (COVID-19) can be significant problems since they cause prolonged clinical manifestations after COVID-19. The aim of this study was to investigate patients with long-term effects of COVID-19 in Aceh Province, Indonesia. Methods: A cross-sectional study was conducted on COVID-19 patients in Aceh, Indonesia using an online survey software tool. The COVID-19 survivors were contacted after a diagnosis of COVID-19 at least 14 days after a negative real time polymerase chain reaction (RT-PCR) result. Results: A total of 303 respondents were contacted after a diagnosis of COVID-19 at least 14 days after a negative RT-PCR result. The results showed that 31% experienced long COVID until the 14th to 15th day of the month, while 69% did not offer long COVID symptoms. The most common symptoms experienced by the patients were fatigue (9.9%), headache (8.7%), and joint and muscle pain (8.1%). Other symptoms reported by COVID-19 survivors were polypnea and shortness of breath, sleep disturbances, coughing, hair loss, palpitations, runny nose, stuffy nose, mental health problems such as anxiety, impaired concentration and depression. The long COVID symptoms were more experienced by female respondents (64.9%) than male respondents (35.1%). Conclusion: Our data suggested that the symptoms of long COVID or long-term consequences of COVID-19 were relatively high. Therefore, measures should be taken to prevent long-term effects among COVID-19 survivors.
- 16 May 2023
- Published by DiscoverSys, Inc. in Bali Medical Journal
- Vol. 12 (3) , 3326-3330
Open AccessThe prevalence of long COVID symptoms in Indonesia: a cross-sectional study in Aceh
Introduction: It is estimated that the long-term consequences of Coronavirus Disease 2019 (COVID-19) can be significant problems since they cause prolonged clinical manifestations after COVID-19. The aim of this study was to investigate patients with long-term effects of COVID-19 in Aceh Province, Indonesia. Methods: A cross-sectional study was conducted on COVID-19 patients in Aceh, Indonesia using an online survey software tool. The COVID-19 survivors were contacted after a diagnosis of COVID-19 at least 14 days after a negative real time polymerase chain reaction (RT-PCR) result. Results: A total of 303 respondents were contacted after a diagnosis of COVID-19 at least 14 days after a negative RT-PCR result. The results showed that 31% experienced long COVID until the 14th to 15th day of the month, while 69% did not offer long COVID symptoms. The most common symptoms experienced by the patients were fatigue (9.9%), headache (8.7%), and joint and muscle pain (8.1%). Other symptoms reported by COVID-19 survivors were polypnea and shortness of breath, sleep disturbances, coughing, hair loss, palpitations, runny nose, stuffy nose, mental health problems such as anxiety, impaired concentration and depression. The long COVID symptoms were more experienced by female respondents (64.9%) than male respondents (35.1%). Conclusion: Our data suggested that the symptoms of long COVID or long-term consequences of COVID-19 were relatively high. Therefore, measures should be taken to prevent long-term effects among COVID-19 survivors.